{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:02:07Z","timestamp":1778940127264,"version":"3.51.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hepatitis B Virus (HBV) is a major driver of infectious disease mortality. Curative therapies are needed and ideally should induce CD8 T cell-mediated clearance of infected hepatocytes plus anti-hepatitis B surface antigen (HBsAg) antibodies (anti-HBs) to neutralize residual virus. We developed a novel therapeutic vaccine using non-replicating arenavirus vectors. Antigens were screened for genotype conservation and magnitude and genotype reactivity of T cell response, then cloned into Pichinde virus (PICV) vectors (recombinant PICV, GS-2829) and lymphocytic choriomeningitis virus (LCMV) vectors (replication-incompetent, GS-6779). Alternating immunizations with GS-2829 and GS-6779 induced high-magnitude HBV T cell responses, and high anti-HBs titers. Dose schedule optimization in macaques achieved strong polyfunctional CD8 T cell responses against core, HBsAg, and polymerase and high titer anti-HBs. In AAV-HBV mice, GS-2829 and GS-6779 were efficacious in animals with low pre-treatment serum HBsAg. Based on these results, GS-2829 and GS-6779 could become a central component of cure regimens.<\/jats:p>","DOI":"10.1093\/infdis\/jiad340","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T12:05:27Z","timestamp":1692619527000},"page":"1077-1087","source":"Crossref","is-referenced-by-count":5,"title":["Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus\u2013Specific CD8 T-Cell Responses and High Anti\u2013Hepatitis B Surface Antigen Titers"],"prefix":"10.1093","volume":"229","author":[{"given":"Sarah","family":"Schmidt","sequence":"first","affiliation":[{"name":"Hookipa Pharma , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meron","family":"Mengistu","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Daffis","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Ahmadi-Erber","sequence":"additional","affiliation":[{"name":"Hookipa Pharma , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Deutschmann","sequence":"additional","affiliation":[{"name":"Hookipa Pharma , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetiana","family":"Grigoriev","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Chu","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cleo","family":"Leung","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Tomkinson","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Nizam","family":"Uddin","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbial Disease, Albany Medical College , Albany, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safiehkhatoon","family":"Moshkani","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbial Disease, Albany Medical College , Albany, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D","family":"Robek","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbial Disease, Albany Medical College , Albany, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Perry","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Lauterbach","sequence":"additional","affiliation":[{"name":"Hookipa Pharma , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Orlinger","sequence":"additional","affiliation":[{"name":"Hookipa Pharma , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon P","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Balsitis","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"2024041213312878400_jiad340-B1","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/d41586-022-00811-2","article-title":"Hepatitis B","volume":"603","author":"Brody","year":"2022","journal-title":"Nature"},{"key":"2024041213312878400_jiad340-B2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.gastro.2022.10.008","article-title":"Current best practice in hepatitis B management and understanding long-term prospects for cure","volume":"164","author":"Yardeni","year":"2022","journal-title":"Gastroenterology"},{"key":"2024041213312878400_jiad340-B3","doi-asserted-by":"crossref","first-page":"e161818","DOI":"10.1172\/JCI161818","article-title":"Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment","volume":"132","author":"Grudda","year":"2022","journal-title":"J Clin Invest"},{"key":"2024041213312878400_jiad340-B4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jhep.2017.09.018","article-title":"Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients","volume":"68","author":"Yip","year":"2017","journal-title":"J Hepatol"},{"key":"2024041213312878400_jiad340-B5","doi-asserted-by":"crossref","first-page":"e1232","DOI":"10.1002\/cti2.1232","article-title":"Designing the next-generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures","volume":"10","author":"Jansen","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"2024041213312878400_jiad340-B6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J Hepatol"},{"key":"2024041213312878400_jiad340-B7","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/infdis\/jiaa121","article-title":"A randomized dose-escalating phase I trial of a replication-deficient lymphocytic choriomeningitis virus vector-based vaccine against human cytomegalovirus","volume":"225","author":"Schwendinger","year":"2022","journal-title":"J Infect Dis"},{"key":"2024041213312878400_jiad340-B8","doi-asserted-by":"crossref","first-page":"115ra111","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Transl Med"},{"key":"2024041213312878400_jiad340-B9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"2024041213312878400_jiad340-B10","doi-asserted-by":"crossref","first-page":"100209","DOI":"10.1016\/j.xcrm.2021.100209","article-title":"Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack","volume":"2","author":"Bonilla","year":"2021","journal-title":"Cell Rep Med"},{"key":"2024041213312878400_jiad340-B11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nm.2104","article-title":"Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity","volume":"16","author":"Flatz","year":"2010","journal-title":"Nat Med"},{"key":"2024041213312878400_jiad340-B12","doi-asserted-by":"crossref","first-page":"e1005276","DOI":"10.1371\/journal.ppat.1005276","article-title":"Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection","volume":"11","author":"Sommerstein","year":"2015","journal-title":"PLoS Pathog"},{"key":"2024041213312878400_jiad340-B13","doi-asserted-by":"crossref","first-page":"e00300","DOI":"10.1128\/CVI.00300-16","article-title":"Additive protection against congenital cytomegalovirus conferred by combined glycoprotein B\/pp65 vaccination using a lymphocytic choriomeningitis virus vector","volume":"24","author":"Schleiss","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"2024041213312878400_jiad340-B14","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.vaccine.2016.03.005","article-title":"Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection","volume":"34","author":"Cardin","year":"2016","journal-title":"Vaccine"},{"key":"2024041213312878400_jiad340-B15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00335-015-9595-6","article-title":"Collaborative cross and diversity outbred data resources in the mouse phenome database","volume":"26","author":"Bogue","year":"2015","journal-title":"Mamm Genome"},{"key":"2024041213312878400_jiad340-B16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/cmi.2013.43","article-title":"A mouse model for HBV immunotolerance and immunotherapy","volume":"11","author":"Yang","year":"2014","journal-title":"Cell Mol Immunol"},{"key":"2024041213312878400_jiad340-B17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1128\/jvi.64.2.613-620.1990","article-title":"Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity","volume":"64","author":"Radziwill","year":"1990","journal-title":"J Virol"},{"key":"2024041213312878400_jiad340-B18","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1038\/s41598-017-02460-2","article-title":"Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"2024041213312878400_jiad340-B19","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.4049\/jimmunol.175.9.5895","article-title":"Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets","volume":"175","author":"Willinger","year":"2005","journal-title":"J Immunol"},{"key":"2024041213312878400_jiad340-B20","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1172\/JCI124098","article-title":"Entering the spotlight: hepatitis B surface antigen-specific B cells","volume":"128","author":"Neumann-Haefelin","year":"2018","journal-title":"J Clin Invest"},{"key":"2024041213312878400_jiad340-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vaccine.2016.11.063","article-title":"Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens","volume":"35","author":"Penaloza MacMaster","year":"2017","journal-title":"Vaccine"},{"key":"2024041213312878400_jiad340-B22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41541-020-00240-0","article-title":"Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans","volume":"5:","author":"Capone","year":"2020","journal-title":"NPJ Vaccines"},{"key":"2024041213312878400_jiad340-B23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat Med"},{"key":"2024041213312878400_jiad340-B24","doi-asserted-by":"crossref","first-page":"e1000455","DOI":"10.1371\/journal.ppat.1000455","article-title":"Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from Southern Africa","volume":"5","author":"Briese","year":"2009","journal-title":"PLoS Pathog"},{"key":"2024041213312878400_jiad340-B25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nm.2108","article-title":"Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys","volume":"16","author":"Santra","year":"2010","journal-title":"Nat Med"},{"key":"2024041213312878400_jiad340-B26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nm.2089","article-title":"Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys","volume":"16","author":"Barouch","year":"2010","journal-title":"Nat Med"},{"key":"2024041213312878400_jiad340-B27","doi-asserted-by":"crossref","first-page":"33987","DOI":"10.1038\/srep33987","article-title":"Epigraph: a vaccine design tool applied to an HIV therapeutic vaccine and a pan-filovirus vaccine","volume":"6","author":"Theiler","year":"2016","journal-title":"Sci Rep"},{"key":"2024041213312878400_jiad340-B28","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"key":"2024041213312878400_jiad340-B29","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(22)02030-X","article-title":"Phase 1b\/2a study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB on nucleos(t)ide analogues","author":"Evans","year":"2022"},{"key":"2024041213312878400_jiad340-B30","doi-asserted-by":"crossref","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathog"},{"key":"2024041213312878400_jiad340-B31","doi-asserted-by":"crossref","first-page":"10808","DOI":"10.1038\/s41598-019-47149-w","article-title":"Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection","volume":"9","author":"Kosinska","year":"2019","journal-title":"Sci Rep"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad340\/51678581\/jiad340.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/4\/1077\/57223348\/jiad340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/4\/1077\/57223348\/jiad340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T13:31:44Z","timestamp":1712928704000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/229\/4\/1077\/7246600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8,21]]},"published-print":{"date-parts":[[2024,4,12]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad340","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,15]]},"published":{"date-parts":[[2023,8,21]]}}}